Back to top
more

Envista (NVST)

(Real Time Quote from BATS)

$16.35 USD

16.35
1,112,796

-0.15 (-0.91%)

Updated Aug 9, 2024 11:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott's (ABT) Amplatzer Amulet Occluder Trial Data Favorable

by Zacks Equity Research

Abbott's (ABT) Amulet IDE trial findings supported the recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation.

Hill-Rom (HRC) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Hill-Rom (HRC) on impressive third-quarter fiscal 2021 performance and raised 2021 guidance.

Labcorp (LH) Base Business Grows Amid a Tough Volume Scenario

by Zacks Equity Research

LabCorp (LH) plans to acquire the autoimmune business unit from Myriad Genetics, including Vectra, a rheumatoid arthritis assay.

Abbott's (ABT) Heart Failure Device Study Outcome Favorable

by Zacks Equity Research

Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.

Medtronic's (MDT) Micra TPS CED Study Outcome Favorable

by Zacks Equity Research

Medtronic's (MDT) Micra TPS new study data supports the relationship of a lower risk of complications with leadless pacing.

Here's Why You Should Hold on to LabCorp (LH) Stock Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) on recovery in its base business and a raised 2021 guidance.

Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges

by Zacks Equity Research

According to Illumina (ILMN), GRAIL will continue to operate as a separate company until the ongoing regulatory review by the EC is completed.

Kinjel Shah headshot

7 Value Stocks to Unlock Gains Using Price-to-Book Ratio

by Kinjel Shah

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

Walgreens (WBA) Provides Flu Shots Nationwide for Ages 3 & More

by Zacks Equity Research

Walgreens (WBA) is ready to co-administer COVID-19 vaccines and flu shots anticipating COVID-19 boosters in September.

Omnicell (OMCL) Enhances Medication Management With New Release

by Zacks Equity Research

Omnicell's (OMCL) Summer 2021 Release offers greater platform deployment options, providing customers better flexibility and improving time to value for strategic initiatives.

    Abbott's (ABT) Base Volume Rebounds, Lowered View Concerns

    by Zacks Equity Research

    Abbott's (ABT) Diabetes Care business has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

      Here's Why You Should Retain Patterson Companies (PDCO) Stock

      by Zacks Equity Research

      Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business. However, high debt level remains a woe.

        Quest Diagnostics (DGX) Acquires Florida-Based NLS Assets

        by Zacks Equity Research

        Quest Diagnostics (DGX) expects the acquisition to broaden the company's spectrum in diagnostic innovation and insights.

          Medtronic (MDT) Receives FDA Nod for Evolut FX TAVR System

          by Zacks Equity Research

          Medtronic's (MDT) Evolut FX TAVR system offers hemodynamic and durability benefits of the Evolut platform with new product and procedure enhancements.

          NVST vs. BSX: Which Stock Should Value Investors Buy Now?

          by Zacks Equity Research

          NVST vs. BSX: Which Stock Is the Better Value Option?

          Hologic (HOLX) Acessa Procedure Gets Anthem Insurance Coverage

          by Zacks Equity Research

          Hologic's (HOLX) Acessa Procedure's new coverage upholds Laparoscopic Radiofrequency Ablation for women suffering from uterine fibroids.

          Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

          by Zacks Equity Research

          Investors are optimistic about Thermo Fisher (TMO) on robust segmental growth and raised 2021 guidance.

          Here's Why You Should Hold on to NextGen (NXGN) Stock Now

          by Zacks Equity Research

          NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. However, intense competition woes linger.

          Masimo's (MASI) Noninvasive Continuous PVi Favored by New Study

          by Zacks Equity Research

          Masimo (MASI) reports study findings that will aid clinicians in getting meaningful information with respect to monitoring the volume status in critically ill patients with spontaneous breathing.

          Intersect ENT's (XENT) Sell Off Plan Strategic Amid Pandemic

          by Zacks Equity Research

          Intersect ENT's (XENT) top-line growth from the PROPEL family of products and SINUVA continues to be challenged by seasonal variations in the volume of sinus surgery procedures.

          Bruker (BRKR) Hits a New 52-Week High: What's Driving It?

          by Zacks Equity Research

          Investors are optimistic about Bruker (BRKR) on solid BSI Nano Group growth potential and raised 2021 financial guidance.

          Here's Why You Should Invest in West Pharmaceutical (WST) Now

          by Zacks Equity Research

          West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

          Illumina (ILMN) Shares Slip on GRAIL Buyout Deal Completion

          by Zacks Equity Research

          Illumina (ILMN) acquisition of GRAIL will expand patient access to life-saving multi-cancer early-detection test.

          Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now

          by Zacks Equity Research

          Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and raised 2021 outlook.

          Here's Why You Should Retain Cooper Companies (COO) Stock Now

          by Zacks Equity Research

          Cooper Companies (COO) continues to benefit from strength in its business segments.